A Single Ascending Dose Study of DT-216P2 in Normal Healthy Participants
A Single Ascending Dose Study of DT-216P2 in Normal Healthy Participants
Not yet recruiting · NCT06772870 · Registry updated 2025-02-21Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Single Ascending Dose Study of DT-216P2 in Normal Healthy Participants | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Friedreich ataxia, Nutritional and Metabolic Diseases, Spinocerebellar Degenerations, brain disorder, central nervous system disorder, cerebellar disorder, hereditary disease, inborn mitochondrial metabolism disorder, inherited neurodegenerative disorder, metabolic disease, nervous system disorder, neurodegenerative disease, spinal cord disorder | Not yet recruiting | Phase 1 | 2025-02-21 | NCT06772870 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Design Therapeutics, Inc. | 3 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Nucleus Network, Level 5, 89 Commercial Road | Melbourne | Australia | 1 |